Literature DB >> 10695266

Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease.

P Ferroni1, S Basili, F Martini, M Vieri, G Labbadia, C Cordova, C Alessandri, P P Gazzaniga, S Basil.   

Abstract

A comparative analysis between soluble (s) P-selectin and von Willebrand Factor (vWF) was performed in 40 patients with chronic obstructive pulmonary disease (COPD) and 20 healthy subjects, with the aim of investigating whether the occurrence of elevated levels of sP-selectin may reflect activation of platelets, endothelial cells, or both. Plasma sP-selectin levels were significantly higher in patients compared to controls (P < 0.01). Similarly vWF levels were elevated in patients compared to healthy subjects, although the difference did not reach statistical significance. Lipoprotein (a) [Lp(a)] levels were lower in COPD patients than controls (P < 0.0001). The analysis of the correlation among all the variables demonstrated that plasma sP-selectin did not correlate with vWE. Conversely, plasma sP-selectin levels significantly correlated with either oxygen (rho = -0.41, P < 0.05) or carbon dioxide (rho = 0.47, P < 0.05) tension. An inverse correlation between serum Lp(a) and plasma sP-selectin levels (rho = -0.35, P < 0.05) was also observed. Moreover, increasing levels of sP-selectin in COPD patients significantly correlated with the impairment of blood gas tensions. In conclusion, the results obtained indicate the prominent platelet origin of circulating sP-selectin, suggesting that sP-selectin might be considered a marker of in vivo platelet activation in patients with COPD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10695266

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  7 in total

1.  P-selectin glycoprotein ligand-1 (PSGL-1) is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease.

Authors:  A Schumacher; U Liebers; M John; V Gerl; M Meyer; C Witt; G Wolff
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

2.  Adhesion molecules, endothelin-1 and lung function in seven population-based cohorts.

Authors:  E C Oelsner; T D Pottinger; K M Burkart; M Allison; S G Buxbaum; N N Hansel; R Kumar; E K Larkin; L A Lange; L R Loehr; S J London; G T O'Connor; G Papanicolaou; M F Petrini; D Rabinowitz; S Raghavan; S Redline; B Thyagarajan; R P Tracy; J B Wilk; W B White; S S Rich; R G Barr
Journal:  Biomarkers       Date:  2013-04-05       Impact factor: 2.658

Review 3.  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.

Authors:  S E Kahn
Journal:  Diabetologia       Date:  2003-01-11       Impact factor: 10.122

Review 4.  Novel uses for anti-platelet agents as anti-inflammatory drugs.

Authors:  S C Pitchford
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

Review 5.  NETosis in Cancer - Platelet-Neutrophil Crosstalk Promotes Tumor-Associated Pathology.

Authors:  Anna-Karin Olsson; Jessica Cedervall
Journal:  Front Immunol       Date:  2016-09-21       Impact factor: 7.561

6.  Adhesion molecules in subjects with COPD and healthy non-smokers: a cross sectional parallel group study.

Authors:  Kristin Blidberg; Lena Palmberg; Anna James; Bo Billing; Elisabeth Henriksson; Ann-Sofie Lantz; Kjell Larsson; Barbro Dahlén
Journal:  Respir Res       Date:  2013-05-01

7.  Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts.

Authors:  Ashraf Fawzy; Nirupama Putcha; Laura M Paulin; Carrie P Aaron; Wassim W Labaki; MeiLan K Han; Robert A Wise; Richard E Kanner; Russell P Bowler; R Graham Barr; Nadia N Hansel
Journal:  Respir Res       Date:  2018-01-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.